Revenue: ₹5,140 million, representing a 44% year-on-year (YoY) growth and an 8% sequential growth.
Gross Profit: ₹3,330 million, a 39% YoY growth and 7% sequential growth.
R&D Expense: ₹594 million (11.6% of operating revenues), compared to ₹361 million in Q4 FY25 and ₹523 million in Q3 FY26.
Operating EBITDA: ₹1,190 million, a 64% YoY growth.
EBITDA including other income: ₹1,210 million, a 67% YoY growth.
PBT: ₹987 million, a 93% YoY growth.
PAT: ₹768 million, a 112% YoY growth and sequential growth.
Financial Performance (Full Year FY26)
Revenue: ₹17,540 million, a 37% YoY growth.
Gross Profit: ₹11,660 million, a 32% YoY growth.
R&D Expense: ₹1,935 million (11% of revenue), compared to 10.3% in FY25.
Operating EBITDA: ₹4,000 million, a 52% YoY growth.
EBITDA including other income: ₹4,080 million, a 52% YoY growth.
PAT: ₹2,467 million, an 84% YoY growth.
Balance Sheet (as of March 31, 2026)
Shareholder Funds: ₹12,888 million, primarily driven by IPO proceeds.
Borrowings: ₹2,594 million, a reduction from the previous year due to debt repayment.
Fixed Assets: ₹5,726 million, increased due to the acquisition of the Pithampur facility and additional capex.
Net Working Capital: ₹6,163 million, with working capital days at 126 days (vs. 137 days in the previous year).
ROACE: Improved to 36%, even after the Pithampur acquisition (₹149 crore) which is yet to be commercialized.
Cash Flow Statement
Net Cash Flow from Operating Activities (Q4): ₹655 million, despite a tax payout of ₹501 million in the quarter.
Net Cash Flow from Operating Activities (FY): ₹2,050 million.
Cash Flow from Investing Activities: Outflow of ₹4,097 million, driven by the Pithampur acquisition, fixed deposits from IPO proceeds, capex of ₹800 million, and other inorganic outflows.
Operational and Business Highlights
Revenue growth is broad-based from both established products and new launches.
Product Concentration: Top 5 products account for 39% of revenue; top 10 account for 57%, in line with previous quarters and reflecting no concentration risk.
Pricing has remained stable due to product and specialty mix.
FDA Approvals: Received 12 product approvals in FY26.
Pipeline: 24 products are currently under review with the US FDA, signaling a robust growth pipeline.
Commercialization Rate: Strong at 92% of approved products.
Specialty Portfolio: Contributed 33% of the quarter's gross profit.
Dividend: The board recommended a dividend of 150% (₹1.5 per share), amounting to a 10% payout ratio.
Gross Margins, Capex, and Manufacturing Strategy
The company's philosophy is to incur capex only after seeing sustained long-term demand, not in anticipation.
Due to demand exceeding expectations, the company increased reliance on outsourced manufacturing in the short term, leading to a slight decline in gross margins.
This reliance on outsourced manufacturing is expected to continue for at least a couple more quarters.
The Pithampur facility acquisition is on track. The site is qualified, prerequisites are complete, and products have been filed. An FDA inspection is awaited.
The initial indication for a ramp-up remains Q1 of Calendar Year 2027 (likely Q4 FY27).
Management reiterates an EBITDA margin guidance range of 22% to 23% (Q4 margin was 23.1%).
R&D Spend and Productivity
R&D spend is a lead indicator of future revenue.
R&D Productivity Multiple (FY26 over FY23): Incremental revenue of ₹13.46 billion against an R&D spend of ₹2.26 billion over nine quarters, resulting in a 5.9x multiple.
R&D Spend Guidance: Target of ₹5 billion (₹500 crores) over the nine quarters of FY26, FY27, and Q1 FY28 remains on track with high confidence.
ESOP Pool
The board approved a proposal to create an ESOP pool, subject to shareholders' approval, to attract and retain talent.
The P&L impact of the ESOP has been factored into the EBITDA guidance.
Acquisition of Arinna Lifesciences
Purpose: Extension of strategy to build a global therapeutics platform focused on CNS and chronic areas. Provides an entry into the under-penetrated Indian CNS market and an additional avenue to monetize the pipeline.
Deal Contours: Acquired an 85% stake for an enterprise value of ₹200 crore on a cash and debt-free basis. Deal value was approximately ₹176 crore (₹158.53 per share).
Rationale: Arinna provides a commercial starting point with over 4,000 prescribers and an established distribution network, enabling faster penetration for Rubicon's specialty and drug-device products.
Management: Founder Mr. Vivek Seth continues as Managing Director, bringing over 30 years of experience in the CNS space.
Strategy: The acquisition aligns with Rubicon's M&A history of focusing on capability building (e.g., Impopharma Canada, manufacturing sites). The focus for the next few quarters will be on laying the foundation for growth, with confidence in beating Indian Pharmaceutical Market (IPM) growth in FY28.
Financial Impact: The economics and the investment's impact on phases have been factored into the previously provided EBITDA guidance.
Q&A Session Highlights
Product Discontinuation: One product was discontinued in the quarter.
M&A Strategy: The strategy is therapeutic-focused (CNS) rather than geographic-focused. The Arinna acquisition adds a market (India) to this therapeutic focus.
Pithampur Facility: The initial inspection is for the 'general block,' for which there is sufficient demand. The goal is to achieve decent capacity utilization within 12-18 months post-inspection.
Inventory: Higher inventory is in conjunction with high growth rates and is a combination of stock for existing product growth and expected new launches over the next 1-1.5 years.
Capex Guidance: Approximately ₹300 crores is projected across various sites over the next couple of years.
Finance Cost: The sequential increase is due to remaining debt, costs related to receivable factoring, and debt partly funding the Arinna acquisition. Finance cost may not see a significant reduction soon.
Compliance: The company highlighted its strong compliance culture, noting a recent surprise US FDA inspection at its Canadian facility that concluded with zero observations.
EBITDA Guidance Clarification: The 22-23% EBITDA margin guidance incorporates ESOP expenses, Arinna-related expenses, Pithampur-related expenses, and potential raw material/logistics cost escalations, barring any unforeseen black swan events.
